Pharmacophore based drug designing against COL7A1; The causative protein of Dystrophic Epidermolysis Bullosa

Epidermolysis Bullosa is a rare genetic disorder that causes skin fragility, trauma induced dissociations of the skin, and painful wound growth. More than 20 types of genes are involved in causing EB as it is a polygenic disease and each gene is involved in a different subtype of EB. Dystrophic Epidermolysis Bullosa (DEB) is one of the subtypes of EB caused by mutations in the COL7A1 (Collagen Type VII Alpha 1 Chain) gene and it affects people from all racial backgrounds. No drug is available for DEB in the market yet. So, it is the need of the hour to come up with a potential inhibitor that could inhibit the faulty protein of COL7A1 gene. Different exons of COL7A1 have been analyzed and exon no 70 to 75 has been selected which were important for mutational point of view. The mutations in it have been identified and verified using various In-silico tools. The 3D structure of the protein has been retrieved using specific exons which were edited and mutations were introduced in it and it was further checked to analyze its stability, toxicity and solubility of the protein. The inhibitors of COL7A1 have been formed using CAAD techniques (pharmacophore modeling) and the best inhibitor of COL7A1 has been further checked to determine its drug-likeness, solubility, its toxicity, and various physiochemical properties. The constructed inhibitor was found to have the best docking results and found to have good ADMET properties. The developed inhibitor construct showing promising results In-silico and it will also show good results if it would be tested inCopyright © 2021 The Authors. Production and hosting by Department of Life Sciences, University of Management and Technology is licensed under a Creative Commons Attribution 4.0 International License vitro and in-vivo. Thus, it would be a breakthrough to treat DEB using this inhibitor if this inhibitor is constructed and further tested in-vitro.